Top in endocrinology: Menopausal hormone therapy, hypothyroidism prevalence
Click Here to Manage Email Alerts
In the past 20 years, researchers have refined knowledge on the benefits and risks of hormone therapy for symptoms associated with menopause.
Although hormone therapy may not protect against cardiovascular events like many believed in the 1980s and 1990s, experts said it provides menopausal symptom relief and has a favorable benefit-risk profile for symptomatic women in early menopause. A look back at the latest developments in menopausal hormone therapy was the top story in endocrinology last week.
Another top story covered findings that showed the prevalence of hypothyroidism is higher among women during the late menopause transition and postmenopause compared with premenopause.
Read these and more top stories in endocrinology below:
20 years of data lead to changes in perceptions, usage of menopausal HT
During the past 2 decades, Endocrine Today has reported on the latest developments in hormone therapy for symptoms associated with menopause. For its 20th year, the publication is taking a look back. Read more.
Hypothyroidism more prevalent during late perimenopause, postmenopause
The prevalence of hypothyroidism — overt and subclinical — is higher among women during the late menopause transition and postmenopause compared with premenopause, according to study findings. Read more.
Symptomatic diabetic autonomic neuropathy common in adults with type 1 diabetes
About one in five adults with type 1 diabetes reports having symptomatic diabetic autonomic neuropathy, according to study findings published in the Journal of Diabetes and Its Complications. Read more.
DKA more common for Black vs. white people with type 1 diabetes before, during pandemic
Black people with type 1 diabetes were more likely to have a diabetic ketoacidosis event before the COVID-19 pandemic in 2019 than other racial-ethnic groups, and that disparity persisted in 2020, according to study findings. Read more.
Addition of empagliflozin improves daytime glucose in type 1 diabetes
Empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) added to automated insulin delivery or predictive low-glucose suspend systems significantly benefited daytime glucose levels for people with type 1 diabetes, with no extra hypoglycemia risk, according to new data. Read more.